22nd Annual International Congress on Hematologic Malignancies : Focus on Leukemias, Lymphomas and Myeloma

22nd Annual International Congress on Hematologic Malignancies : Focus on Leukemias, Lymphomas and Myeloma is organized by Physicians Education Resource, LLC (PER) and will be held during Mar 01 - 04, 2018 at Diplomat Resort & Spa Hollywood, Hollywood, Florida, United States of America.

The target audience for this medical event is community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies may also participate. This CME Conference has been approved for a maximum of 20.25 AMA PRA Category 1 Credits.

Course Overview :
This Course for facilitates clinicians’ skills to contextualize the wealth of emerging data on how to treat hematologic malignancies, personalize treatment based upon patient and tumor characteristics, and apply novel management strategies to their practices to improve outcomes for their patients.

Back by popular demand! The 3-day meeting will once again be held from Friday through mid afternoon Sunday. As always, agenda topics will focus on methods to practically apply state-of-the-art strategies to your clinical practice settings. This engaging and highly interactive meeting will provide ample opportunity to interact with renowned experts in the management of leukemias, lymphomas, myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, and benign hematologic malignancies. Our faculty will distill practice-changing evidence and recommend methods to place this information in its proper context and apply it to real-world care scenarios you encounter. In doing so, a focus will be placed on how to proactively mitigate and manage treatment-related toxicities associated with new treatment strategies.

Topics:
• Key biomarkers to consider in myeloma management
• CAR T cells and other immunotherapeutic strategies to treat hematologic malignancies.
• New clinical considerations for frontline and maintenance strategies for follicular lymphoma
• New chronic lymphocytic leukemia agents: what patient and drug characteristics will inform sequencing decisions in relapsed/refractory disease
• Novel therapies in acute leukemias and how they may alter treatment standards
• Paradigm-changing strategies in the management of myeloproliferative neoplasms

Learning Objectives :
At the conclusion of this Congress, you should be better prepared to:
• Detail methods by which clinical decision making in the management of hematologic malignancies can be personalized with the use of current and emerging biomarkers
• Describe recent evidence on methods to optimize outcomes and consider them in the context of evolving treatment pathways and their application to individual patient cases
• Explain practical methods to proactively mitigate and manage treatment-related toxicities so that optimized outcomes are not compromised in the management of hematologic malignancies
• Evaluate new mechanistic approaches and compounds undergoing clinical investigation for the management of hematologic malignancies
• State the therapeutic implications of recent evidence on evolving treatment paradigms for patients with hematologic tumors